◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral OPTIONAL-ADD MEDIUM

Aniracetam

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD MEDIUM

Different mechanistic flavor from pramiracetam (mood-bright + creativity + mild anxiolysis vs cognitive sharpness) backed by a B-tier 1991 EU placebo-controlled SDAT trial (n=109, 1500 mg/day, 6 mo, 12-35% SCAG improvement vs 9-19% placebo decline) and Japan post-stroke depression/anxiety use through the 1990s — but healthy-adult cognitive enhancement evidence is thin (one Baylor crossover) and a confirmatory placebo-controlled trial in Japan failed, prompting market withdrawal there. For Dylan-archetype: defensible PRN tool for mood/creativity-flavored sessions where pramiracetam isn't the right fit; requires fat for absorption, doesn't add value chronically given the ~30 min parent-compound half-life, and overlaps mechanistically with citicoline/V4 stack on the cholinergic side. Verdict would upgrade to STRONG-CANDIDATE only if a modern healthy-adult RCT replicated the EU SDAT cognitive signal in cognitively-intact subjects; would downgrade to SKIP-FOR-NOW if any signal of long-term receptor desensitization / cognitive blunting emerged or if Dylan reports paradoxical anxiety on trial dose.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD PRN

    Different mechanistic flavor from pramiracetam (mood-bright + creativity vs cognitive sharpness) — defensible as a PRN tool for creative work, sales calls, social-fluency days. Not a daily driver. Cost trivial ($15-25/month), choline cofactor already covered by V4 citicoline, fat-coadministration easy with V4 DHA. Run as 750 mg BID PRN on creative/social days, not on hard sparring days, separate from pramiracetam-day. Drop if no perceived benefit by week 2 of trial use.

  • 30-50, executive maintenance
    OPTIONAL-ADD PRN

    Same logic — useful tool for mood/creativity-flavored work sessions, not a daily-driver; pramiracetam likely better for pure cognitive output.

  • 50+, mild cognitive decline
    OPTIONAL-ADD

    This is actually the population where the EU SDAT B-tier evidence is strongest (1500 mg/day for 6 months, SCAG improvement). Reasonable to trial as adjunct to a cholinesterase inhibitor or as monotherapy for mild MCI; expect modest benefit, not transformative. Italy/Greece prescribe it for this indication; the evidence is real, just dated.

  • Anxiety-prone
    OPTIONAL-ADD

    Mild anxiolytic effect via D2 + nAChR + 5-HT2A convergence — different mechanism from benzos, theanine, or SSRIs; complementary tool. Watch for paradoxical anxiety in the ~5-10% of users who experience it; if present at 750 mg, drop to 500 mg or skip.

  • High athletic load, tested status
    NEUTRAL

    not on WADA list, not banned, but unscheduled / FDA-unapproved means a contaminated or mislabeled product is a sample-failure risk. Verify COA carefully if used.

  • Sleep-disordered
    NEUTRAL

    Aniracetam is much less sleep-disrupting than modafinil or stimulants. Can be dosed in AM + early afternoon without significant sleep interference for most users. Avoid evening dosing.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    Mood-bright + mild anxiolysis is often what's needed during recovery / illness; the cognitive lift is a bonus. Not the highest-evidence option for this use case (cerebrolysin / BPC-157 are better-targeted), but a defensible tool.

  • Strength/anabolic-focused
    NEUTRAL

    / not applicable. No anabolic mechanism.

▸ Subjective experience (deep)

Acute (single 750-1000 mg dose with a fat-containing meal):

  • Onset 20-45 min. Depends on fat content and gastric transit. Faster on top of an existing meal vs taken alone.
  • Peak 1-2 h. Mood lift, verbal fluency, mild cognitive sharpness, often described as "music sounds better" / "colors more saturated" / "dialogue flows easier in conversation." Some users specifically report a creativity-flavored lift — making associative jumps, producing copy / writing more easily, finding the right word faster. This is the signature distinguishing it from pramiracetam.
  • Mild anxiolysis — present without sedation. Different from theanine (more sensory-flavored, less cognitive-flat) and different from a benzo (no muscle relaxation, no memory impairment, no sedation).
  • Taper 3-5 h. Subjective effects fade as N-anisoyl-GABA clears CSF. No "crash" reported in the typical user report; some report mild headache or fatigue at the 4-6 h post-dose mark, often choline-related.
  • Variability: Substantial. ~10-20% of trial users report no perceived effect at all (most likely candidates: low-fat dosing, individual metabolic variation in N-anisoyl-GABA formation). ~5-10% report paradoxical anxiety / mild overstimulation, especially at higher doses or without choline cofactor.

Chronic (daily 750 mg BID for weeks):

  • Subjective magnitude of effects often decreases over 2-4 weeks of daily use (cross-tolerance with own AMPA-PAM mechanism + likely choline depletion + receptor adaptation). PsychonautWiki estimates ~3-7 days for tolerance to reduce by 50% off-drug, 1-2 weeks for full reset.
  • Mood-bright / anxiolytic effects more durable than the acute creativity lift.
  • Headache risk increases with chronic daily dosing if choline cofactor is inadequate.
  • This is why the standard biohacker pattern is PRN, not daily — and why the Dylan-archetype verdict is OPTIONAL-ADD PRN, not daily-driver.

Honest summary for Dylan: This is the racetam most likely to feel "warm" / "social" / "creative" rather than "sharp" / "focused." If pramiracetam is the cognitive scalpel, aniracetam is the mood-and-flow lubricant. Best use case is creative work, social situations, writing days, sales-call days where verbal fluency matters, or recovery days where mild anxiolysis is wanted without sedation. Worst use case is hard analytical / coding / quantitative work — pramiracetam or modafinil are better tools for that.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Moderate / fast. Subjective magnitude often diminishes within 2-4 weeks of daily use; PsychonautWiki estimates 3-7 days off-drug for 50% reset, 1-2 weeks for full reset.
  • Cross-tolerance: Yes, with all other racetams (AMPA-PAM mechanism overlap; choline-system competition).
  • Recommended cycle (if running it daily): 4 weeks on / 1 week off, or simpler — PRN use only, which is the Dylan-archetype pattern.
  • Reset protocol: 1-2 weeks fully off-racetam (any racetam) for clean reset.
▸ Stacking deep dive

Synergistic with

  • citicoline (already in Dylan's V4 at 500 mg/day Cognizin) — covers the choline cofactor requirement, prevents headache, supports the cholinergic arm of aniracetam's mechanism. The single most important stack-mate.
  • alpha-GPC — alternative choline source; some users prefer for racetam stacks due to higher CNS penetration. Citicoline is fine and already in V4.
  • fat / MCT oil / fish oil softgels — required for absorption. Dylan's V4 fish oil (Carlson Super DHA) at breakfast naturally provides this.
  • modafinil — orthogonal mechanism (DAT/NET inhibition + histaminergic for modafinil; AMPA-PAM + mGluR for aniracetam). No published interaction concerns; theoretically additive on cognitive output. For Dylan: defensible to use aniracetam PRN on a modafinil day for the mood/creativity flavor on top of modafinil's wakefulness and focus.
  • alcar — mitochondrial energy support + acetylcholine precursor; mechanism-aligned with the cholinergic arm. Reasonable PRN combo.

Avoid stacking with

  • other racetams chronically (pramiracetam, oxiracetam, coluracetam, piracetam, phenylpiracetam, nefiracetam, fasoracetam) — cross-tolerance, choline competition, signal-muddying. Pick one racetam at a time. Switching between them on different PRN days is fine; running them in parallel chronically is not.
  • MAOIs (phenelzine, tranylcypromine, moclobemide; high-dose selegiline) — theoretical serotonin-syndrome risk. Low-dose selegiline at 1-2.5 mg (Dylan's V5 plan) is borderline — caution on co-dosing days, ideally separate by several hours.
  • TAK-653 — same general AMPA-PAM family. No mechanistic point in stacking, additive AMPA potentiation, multiplies the "AMPA + subconcussive impact" theoretical concern. Pick one.
  • High-dose stimulants + caffeine + amphetamines — additive cortical excitability; theoretical seizure-threshold concern at the upper end (likely irrelevant at biohacker doses, worth flagging).

Neutral / safe co-administration

  • Dylan's V4 OTC stack (DHA, magnesium glycinate/threonate, citicoline, NAC, phosphatidylserine, curcumin, rhodiola, theanine, glycine/tryptophan, D3+K2, beta-alanine, vitamin C, creatine) — no flagged interactions.
  • BPC-157, TB-500, GHK-Cu (peripheral peptides).
  • Adamax / Semax / Selank — distinct mechanisms.
  • Cerebrolysin — both raise BDNF via different upstream paths; no human stack data; theoretical convergence; default to cycling separately for cleaner signal.
  • Bromantane — orthogonal (DA-synthesis upregulation); no flagged interaction.
  • Theanine, taurine, magnesium — neutral.
  • Apigenin — neutral.
▸ Drug interactions deep dive
  • CYP3A4 / CYP2C19 substrate — aniracetam is hepatically metabolized; strong CYP3A4 inhibitors (ketoconazole, ritonavir, large grapefruit-juice quantities) would theoretically raise exposure; strong inducers (rifampin, St John's Wort) would lower it. No published clinical DDI study.
  • MAOI activity (rat study) — theoretical risk with prescription MAOIs and natural MAOI compounds; see Side effects.
  • Anticholinergics — reduce aniracetam's cognitive effects (mechanism opposed at the cholinergic arm). Also true for diphenhydramine, scopolamine, oxybutynin — these will blunt aniracetam.
  • Alcohol — no specific interaction studied; expect aniracetam to mildly counteract alcohol's cognitive-impairment effect (both via mood and via cholinergic balance), but no substitute for not drinking. Dylan is zero-alcohol baseline so not relevant.
  • Antiplatelets / anticoagulants — piracetam has documented platelet-aggregation inhibition; aniracetam likely shares this to a lesser degree. Of low practical relevance unless combined with prescription antiplatelets (aspirin, clopidogrel) or recent surgery.
▸ Pharmacogenomics
  • CYP2C19 — major metabolic contributor; PM status (relevant in some Asian populations more than Nordic/British) could raise exposure modestly. Dylan's ancestry suggests low PM probability; check 23andMe results when available.
  • CYP3A4 — minor variants; low practical relevance for aniracetam.
  • BDNF Val66Met — mechanistically relevant (BDNF expression is one of the downstream effectors). Met-carriers may show blunted plasticity response. Worth checking 23andMe.
  • GRIA1-GRIA4 (AMPA receptor subunit genes) — no published aniracetam pharmacogenomics tied to GluA polymorphisms.
  • Practical: minimal actionable PGx data exists for aniracetam currently.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem Liftmode ~$0.10-0.15 / 750 mg = ~$15-25/mo at 750 mg BID High Third-party COA per batch; established budget vendor for natural-leaning nootropics. Recommended starting vendor.
Research-chem SwissChems ~$15-20/mo Medium-high Cheapest per-dose pricing on racetams; 20% crypto discount; ships globally. Some quality variability noted in vendor reviews.
Research-chem Cosmic Nootropic ~$20-30/mo Medium-high Russian-leaning vendor (also Dylan's source for Russian peptides — already familiar). Reliable.
Research-chem Limitless Biotech / Absolute Nootropics / PureRawz $20-30/mo Medium Multiple alternative vendors; COA verification recommended.
Research-chem Bulksupplements Variable Medium Possibly carries aniracetam; check current listing.
Avoid Nootropics Depot — Off-market for racetams DOJ enforcement (Centera Bioscience plea Oct 2023, sentenced Feb 2024, $2.4M forfeiture, 3 years probation for the company + 1 year probation for CEO Paul Eftang). Nootropics Depot no longer sells racetams. Was the gold-standard US vendor pre-2024; gone now. Major change since 2023.
Avoid Science.bio — Closed Jan 2026 Permanently re-closed in January 2026.
Avoid Everychem — Blacklisted Per Dylan's vendor blacklist.
Rx Italian / Greek pharmacy (Ampamet / Memodrin) ~$30-50/mo with prescription High If traveling in EU and Rx access available. Not a practical path for Dylan.
Rx Japan — Withdrawn from market No longer available.

Critical sourcing notes (post-2024 landscape):

  1. The US racetam market changed materially in 2023-2024. Before the Centera Bioscience case, Nootropics Depot was the high-quality reference vendor for all racetams in the US. After the DOJ case (plea Oct 2023, sentencing Feb 2024), they exited the racetam category entirely. The current US-accessible racetam landscape is dominated by smaller research-chem vendors with less rigorous QC than Nootropics Depot historically applied. Demand a current batch-specific COA, not a generic certificate.
  2. Cost is low across the board. Even at the higher end, aniracetam runs $15-25/month at 750 mg BID — one of the cheapest CNS-active compounds in the V5 universe. Cost is not a decision driver.
  3. Form factor: Powder is cheapest, capsules are convenient. Powder dosing requires an analytical scale (0.01 g resolution) for 750 mg accuracy; eyeballing a "scoop" is a 2-3× error risk.
  4. Solubility: Aniracetam is poorly water-soluble — capsule + fatty meal is the easy path. If using powder, mix with MCT oil or take with high-fat food rather than dissolving in water.
  5. Customs / legal: US — FDA-unapproved "new drug"; personal-import is a gray area. Possession not criminal; commercial sale to consumers is what triggered the Centera case. Possession/personal-use risk is low operationally but the framing is fragile post-2024.
▸ Biomarkers to track (deep)

Baseline (before starting any trial)

  • Subjective baseline: PHQ-9 (depression), GAD-7 (anxiety), self-rated verbal fluency / creativity, self-rated mood — establish 2-week pre-baseline.
  • Cognitive battery: Cambridge Brain Sciences or n-back; primarily looking for a directional change in working memory or attention rather than a rigorous A-tier signal.
  • Liver panel (AST/ALT) — baseline before any racetam use.

During use (PRN trial weeks)

  • Subjective: mood, creativity, verbal fluency, headache, GI tolerance, sleep onset.
  • If running daily for >4 weeks: liver panel at week 4.
  • Track perceived effect magnitude per dose — if it diminishes meaningfully across 2-4 weeks, that's the tolerance signal indicating a reset is needed.

Post-cycle

  • 1-2 week washout for full receptor reset before re-trialing or comparing to a different compound.
▸ Controversies / open debates Live debate
  • Japan withdrawal: what actually happened. Aniracetam (Draganon) was approved in Japan for emotional disturbances after cerebral infarction (post-stroke depression, anxiety, agitation) — not for memory impairment. After ~8 years of clinical use, Roche was required to run a confirmatory placebo-controlled trial. The trial failed (primary endpoint not met) and aniracetam was withdrawn from the Japanese market in the late 1990s. This is a meaningful negative signal that biohacker community sources rarely emphasize. The Italian + Greek prescription markets remained — the EU SDAT 1991 trial is a separate body of evidence on a different indication (cognitive impairment, not post-stroke mood) — but the Japan failure is a real piece of evidence that the mood/anxiolytic case is weaker than the cognitive-impairment case.
  • Healthy-adult cognitive enhancement: weak signal. The EU SDAT trial worked because subjects had cognitive impairment to correct. Healthy mouse studies (Vaidya 2014, F1000 2017) and the Baylor healthy-adult crossover largely null — aniracetam may be deficit-specific rather than a true cognitive enhancer in cognitively-intact adults. The biohacker corpus disagrees, but the corpus is heterogeneous and not placebo-controlled. For Dylan: the mood/creativity effect is more robustly reported than a pure cognitive lift; expectations should be calibrated accordingly.
  • Half-life confusion across vendor copy. Vendor blogs frequently cite "half-life 1-2.5 h" or "2-3 h" for aniracetam — these are N-anisoyl-GABA metabolite half-lives, not parent compound. Parent aniracetam has a ~30 minute (0.5 h) plasma half-life (Endo et al., 2012). The functional duration of effect (3-5 h) is metabolite-driven. The encyclopedia entry's "2-3 hr half-life" is technically referring to the metabolite, which is fine — but this should be clear in any source-citing pass.
  • Parent vs metabolite as the active species. Most published mechanism work uses aniracetam as the test compound, but rat microdialysis studies confirm N-anisoyl-GABA reproduces most of the cognitive / cholinergic / mood effects when administered directly — and given the parent's 0.2% bioavailability, the metabolite is doing most of the systemic work. This is rarely emphasized but materially changes how to think about timing and pharmacokinetics.
  • 2024 Alzheimer's-prevention model paper: hypothesis, not evidence. The PMC11091568 paper proposing aniracetam upregulates alpha-secretase via BDNF + mGluR is a theoretical model, not new in vivo data. Several biohacker sources cite it as if it were efficacy evidence — it isn't. Treat as mechanism-generating, not efficacy-confirming. A modern preclinical or clinical AD trial of aniracetam has not been run; the lecanemab / donanemab era of anti-amyloid therapeutics has displaced this kind of older mechanism work in actual AD development.
  • Centera Bioscience case: practical implications for sourcing. Pre-2024, Nootropics Depot was the high-QC US vendor for all racetams. The Oct 2023 plea / Feb 2024 sentencing removed them from the racetam market entirely. Current vendors (Liftmode, SwissChems, Limitless Biotech) are smaller, less rigorous on QC, and the post-2024 racetam supply chain has more variability. COA verification is more important now than it was pre-2024.
  • Modern AMPA-PAM context: aniracetam vs second-gen. The clinical AMPA-PAM space has moved on to TAK-653 / osavampator, which is in Phase 3 and operates at 1 mg vs aniracetam's 1500 mg, with much cleaner agonist-deficient profile and 419-1017× safety margins to convulsion. For someone interested in the modern AMPA-PAM mechanism, aniracetam is the prototype with a 50-year safety record at clinical doses but is not where the efficacy / safety frontier lives. For someone interested in mood-bright + creativity + mild anxiolysis as a phenomenology (not just AMPA potentiation in the abstract), aniracetam's metabolite-driven dual-modulator profile is actually distinct and not replicated by TAK-653 — they are different tools, not the same tool with different potencies.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: OPTIONAL-ADD PRN, verdict-confidence MEDIUM. Defensible PRN tool for mood/creativity-flavored sessions; different mechanistic flavor from pramiracetam (the cognitive-sharpness racetam in Dylan's PRN tier). B-tier 1991 EU SDAT trial supports cognitive efficacy in impaired populations; Japan post-stroke depression indication withdrawn after a confirmatory trial failed; healthy-adult cognitive evidence thin; mood/anxiolytic / creativity effect more robustly reported in the user corpus. Cost trivial ($15-25/mo), choline cofactor already covered by V4 citicoline, fat coadministration easy. Verdict would upgrade to STRONG-CANDIDATE only if a modern healthy-adult RCT replicated cognition or mood signal in cognitively-intact subjects; would downgrade to SKIP-FOR-NOW if Dylan reports paradoxical anxiety on trial dose or if any signal of long-term receptor desensitization / cognitive blunting emerges in published work.
▸ Open questions / gaps Open
  • Is there any modern (post-2010) placebo-controlled trial in healthy adults? As far as I can find: no rigorous one. The Baylor crossover is dated and underpowered. A 4-6 week double-blind placebo-controlled trial in healthy adults at 1500 mg/day is the missing evidence piece — this is the experiment that would settle the "deficit-specific or true cognitive enhancer" debate. Unlikely to be run because the molecule is off-patent and unprofitable; biohacker self-experimentation is the de facto data source.
  • What was the exact failed-trial design that led to Japan's aniracetam withdrawal? Specific trial name, sample size, primary endpoint, and effect-size are surprisingly hard to find in English literature. Worth a re-search at next review (2026-11-05) — the conclusion that "the post-stroke mood indication is on weaker evidence than the cognitive-impairment indication" is robust either way, but the specifics matter for full-evidence framing.
  • Long-term safety past 1-2 years in healthy adults using daily. No published cohort. Italy/Greece prescription use exists but mostly in elderly populations with cognitive impairment — not a clean source for healthy-adult chronic-use safety.
  • 2024 alpha-secretase / amyloid-prevention hypothesis: any in vivo data 2026+? Worth tracking if any preclinical or pilot human work emerges in the next 12 months — a positive result would meaningfully change the longevity / brain-protection framing for the compound.
  • MAOI interaction: clinical relevance at biohacker doses? The MAOI-activity rat study is one paper. Magnitude in humans at 750-1500 mg oral is unknown; serotonin-syndrome reports in the user corpus are absent. The interaction warning is theoretical-conservative; for Dylan combined with planned low-dose selegiline (1-2.5 mg), real risk is probably very low but not zero. Worth flagging.
  • Pharmacogenomics — does CYP2C19 PM or BDNF Val66Met genotype predict response? Untested. 23andMe data may become useful if Dylan trials it.
▸ Sources (full, with our context)
Back to compact view